AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04811729 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: The participants will apply an approach based on the Motivational Interview (Rollnick, 2008) in patients with excessive alcohol consumption, previously receiving a training program
Study NCT04811729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical advice
Description: Usual care
Study NCT04701216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8735
Description: SHR8735 is an thrombopoietin receptor agonist to promote platelet production.
Study NCT06166511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Description: Using Laparoscopy in liver resection
Study NCT05530954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate (MTA)
Description: Materials for Vital Pulp Capping
Study NCT05530954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hard setting Calcium Hydroxide (Dycal)
Description: Materials for Vital Pulp Capping
Study NCT03259698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nPEP
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.
Study NCT03259698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nPEP
Description: Participants will receive Bictegravir/emtricitabine/tenofovir alafenamide 50/200/25mg (Biktarvy®) one tablet once daily as study drug to complete a 28 day course of PEP.
Study NCT03259698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging Support
Description: Text messaging support service ('WelTel'): community-based counselors will provides standardized weekly 'check-in' messages during the participants 12-week course of nPEP follow-up. Participants in the text-message arm will also have the option of receiving generic non-specific automated text reminders of their upcoming appointments in the form of Don't forget about tomorrow.
Study NCT03259698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-Led nPEP
Description: nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
Study NCT05040178 — intervention group
Intervention type: DRUG
Intervention: Carglumic Acid
Description: Current or previous treatment with Carbaglu, the dose of Carbaglu® prescribed will be determined by the investigator for each individual patient.
Study NCT05082571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: Vadadustat tablet orally once a day for 52 weeks
Study NCT04830748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical knee traction
Description: Continuous knee joint mechanical traction will be applied to the patients positioned in supine lying position with the affected knee flexed at 25-30 degrees by a wedge placed under the affected knee. The thigh will be secured with a strap for stabilization and the leg will be held by the specially designed greave with the weight of traction hanging throughout a pulley system. The amount of traction will be set to about 10% of body weight. The treatment will be applied for 20 minutes continuously, once a day, 3 times per week for 4 weeks. The traction force will be progressed gradually during the program ( e.g.: weekly increase force by 1% of body weight if the patient can tolerate the duration of 20 min with the preset force).
Study NCT04830748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force.
Study NCT04830748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Therapeutic exercises will be divided into stretching and strengthening exercises:~Stretching will be done passively for the hamstring, rectus femoris and calf muscles. Each exercise will be done for 3 reps each with a hold period of 30-60 secs with a 30-60 rest period between reps.~Strengthening exercises will be done for the quadriceps and hamstring muscles ( inner range knee extension- knee extension in sitting- straight leg raise in flexion- prone hamstring curl- standing hamstring curl- straight leg raise in extension). Exercise will be done for 3 sets each will consist of 10 reps with a rest period of 2-3 minutes between sets. The starting weight should be 50% of the patient's 1 RM. The end position will be held for 5 seconds. Progression will be achieved by increasing the exercise rep and intensity gradually throughout the program. E.g.: weekly increase force by 5% if patient can tolerate an increased repetition of 20 rep with the preset force.
Study NCT04971837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Oil based tincture formulation
Description: 30 mg CBD isolate in MCT oil,1:1 ratio of CBD to Medium Chain Triglycerides oil. (Formulation 088: Not water soluble. Contains medium chain triglyceride coconut oil.)
Study NCT04971837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Gum Arabic, maltodextrin base formulation
Description: 10% CBD Gum Arabic, maltodextrin base(Formulation 126: Water soluble. Contains gum arabic and maltodextrin)
Study NCT04971837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Gum Arabic, sorbitol base formulation
Description: 10% CBD Gum Arabic, sorbitol base (Formulation 213: Water soluble. Contains gum arabic and sorbitol)
Study NCT04971837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Isolate in water formulation
Description: Pure CBD as crystalline powder (>99% purity) (Formulation 625 Not water soluble)
Study NCT04971837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CBD matching Placebo
Description: Matching Placebo
Study NCT05706415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinicians will review the suggestions of a hypothetical AI
Description: There is no intervention. Clinicians will review the suggestions of a hypothetical AI
Study NCT05388071 — intervention group
Intervention type: OTHER
Intervention: Usage of telemedicine and tele-consultation for treatment
Description: Telemedicine will be used to treat patients at an ambulance station. The medical interventions will be performed by a TeleSAN after delegation through a tele-EMS-physician if possible.
Study NCT05878132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable device -'Smart Reminder'
Description: The wearable device, a wristwatch, has a Bluetooth function to link to mobile devices for the participants to view the prescribed videos and engage in telerehabilitation. It has sensors to monitor arm movements and provides multiple feedbacks (auditory, visual and tactile). Participants were instructed to practice the prescribed exercises -tailored according to the severity of UL paresis for the recommended therapy dose. The device recorded the angles of arm movement and the number of repetitions completed and data collected is uploaded to an encrypted cloud server for remote monitoring. Weekly, the participants will receive a 30-minute consultation session to review their progress and modify prescribed exercises based on the wearable device data.
Study NCT05878132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: The participants in the control group received similar in-home upper limb exercises as the wearable device group, with the prescribed exercises presented in the form of a pictorial handout rather than an in-app video. They were instructed to perform the exercises for the recommended therapy dose and received a weekly therapy consultation as well. To monitor the participant's exercise compliance, they were instructed to record their daily exercise progress in the exercise log.
Study NCT05319015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Lenvatinib
Description: 20 mg PO daily for 12 weeks prior to surgery
Study NCT05319015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Pembrolizumab
Description: 200 mg IV every 3 weeks for 4 doses prior to surgery
Study NCT05319015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
Description: Resection of locally advanced RCC with IVC tumor thrombus
Study NCT05319015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Pembrolizumab
Description: 200 mg IV every 3 weeks for up to 13 doses after surgery
Study NCT04964466 — intervention group
Intervention type: BIOLOGICAL
Intervention: Amount of PDGF-BB in PRF preparation vs. GEM21
Description: The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
Study NCT04964466 — intervention group
Intervention type: BIOLOGICAL
Intervention: Amount of PDGF-BB available in PRF + bone substitutes vs. rhPDGF-BB+ bone substitutes following preparation
Description: Growth factor release assessments will be made to determine the PDGF-BB present in the six prepared samples of the following: 1) PRF + mineralized freeze-dried corticocancellous allograft, 2) PRF + xenograft, and 3) PRF + B-TCP. Assessments will also be made for one sample of each of the following: 1) rhPDGF-BB + freeze-dried bone allograft, 2) rhPDGF-BB + xenograft, and 3) rhPDGF-BB+ B-TCP preparation. This assessment will be made at 60 minutes following the incorporation of the bone graft materials. During this time period, the samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At 60 minutes after preparation, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
Study NCT04964466 — intervention group
Intervention type: BIOLOGICAL
Intervention: Release kinetics of PDGF-BB in PRF + bone substitutes vs. rhPDGF-BB + bone substitutes
Description: The release kinetics of PDGF-BB will be assessed for six preparations of each of following: 1) PRF+ mineralized freeze-dried corticocancellous allograft, 2) PRF + bone xenograft, and 3) PRF + B-TCP. The release kinetics of PDGF-BB will also be assessed for one preparations of each of following: 1) rhPDGF-BB + mineralized freeze-dried corticocancellous allograft, 2) rhPDGF-BB + bone xenograft, 3) rhPDGF-BB + TCP. The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
Study NCT04964466 — intervention group
Intervention type: BIOLOGICAL
Intervention: Release kinetics of PDGF-BB in rhPDGF-BB + PRF + bone substitutes
Description: The quantification will be performed at 60 minutes, 8 hours, 1 day, 3 days, and 10 days. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol. The samples will each be placed in a cell incubator at 37°C to allow for growth factor release into a phosphate-buffered saline. At each desired time point assessment, 2 ml of the sample will be collected, frozen, and replaced with 2 ml of additional phosphate-buffered saline. The protein quantification will be carried out using ELISA assay according to manufacturer's protocol.
Study NCT05980455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enterra® Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study NCT05831631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating leukocytes immunophenotype
Description: Blood samples will be tested with flow cytometry in order to characterize leukocyte subpopulations and to evaluate the circulating immunophenotype
Study NCT05831631 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor sampling
Description: Immunohistochemical analysis will be performed on tumor samples in order to characterize immune T cells distribution within the tumor.
Study NCT06568783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FAPI-74
Description: \[18F\]-FAPI-74 7 mCi ± 20% administered intravenously.
Study NCT06074601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mirvie Predictive Test for Adverse Pregnancy Outcomes
Description: This is a proprietary biomarker and clinical factor-based algorithm for predicting which pregnancies are at greatest risk of developing a variety of adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)
Study NCT03923322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botanical Tincture
Description: Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. Participants randomized to Botanical Tincture will have a 2-week withdrawal period. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
Study NCT03923322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will meet with the Investigator at baseline and week 2, 6, and 10 after the study period begins. Trial continuation criteria at 2 weeks after the start of the study includes abdominal pain intensity and stool frequency. On the visits study participants may expect to be asked about epidemiologic information, IBS medications, IBS Quality of Life survey instruments, and daily diary of pain scale, bloating scale, and number of bowel movements.
Study NCT05331027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±5.
Study NCT05331027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After induction of anesthesia maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±5.
Study NCT06169397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTMAB-16
Description: XTMAB-16 infusion
Study NCT06139692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients receive perioperative sedation with dexmedetomidine
Study NCT06139692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patients receive perioperative sedation with midazolam
Study NCT06560021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy strategy
Description: Number of random biopsies, in addition to targeted biopsies, taken during colonoscopies where at least one indication for the colonoscopy is surveillance for dysplasia
Study NCT06458959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEM+
Description: The Young Children's Participation in Environment Measure (YC-PEM), an evidence-based and promising electronic patient-reported outcome (e-PRO) when combined with the Participation and Environment Measure Plus (PEM+) care planning application that yields a summary report and is paired with a program-specific decision-support tool, may support family engaged Early Intervention (EI) service plan development. Intervention group caregivers will complete the YC-PEM e-PRO and PEM+ intervention before their child's annual review of progress. The online summary report will be combined with a program-specific decision-support tool to guide EI service plan development.
Study NCT05980455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enterra® Therapy System
Description: The Enterra® Therapy System for gastric electrical stimulation (GES) is indicated for the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years.
Study NCT06558214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Keytruda® is the trade name for pembrolizumab, which will be given as 200mg IV Q3 weeks. This treatment will continue for up to two years.
Study NCT06558214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optune GIO®
Description: .~. Optune GIO® TTFields treatment will begin 3-7 days prior to MLA for Arm1 and 3-10 days prior to MLA for Arm 2.
Study NCT06558214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroBlate®
Description: Treatment with NeuroBlate will occur one time at the beginning of the study.
Study NCT06375564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-AB-3PRGD2 radioligand therapy
Description: Radioligand therapy using 177Lu-AB-3PRGD2 80 mCi (2.96 GBq) will be performed 6-weekly. A maximum of 4 cycles will be administered.
Study NCT04722653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: 1 single dose administered subcutaneously (s.c. - under the skin)
Study NCT04722653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NNC0194-0499 )
Description: 1 single dose administered subcutaneously (s.c. - under the skin).
Study NCT06082271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Class III medical Hydrolyzed Collagen Peptides PEP-52 (Peptys)
Description: Anti-inflammatory and regenerative effect, 5 mg/ml
Study NCT06082271 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone
Description: DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
Study NCT06278909 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trigeminal Nerve Stimulation
Description: Active trigeminal nerve stimulation
Study NCT05893797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: As prescribed.
Study NCT05893797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tempo Smart Button
Description: Attached to the Tempo Pen
Study NCT05893797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Continuous glucose monitor
Study NCT05893797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glooko Research Medical App (RMA)
Description: Installed on a study provided android phone.
Study NCT06005103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with MoodHeadBand (T-PEMF treatment)
Description: The patients will receive treatment with T-PEMF using a headband containing 20 coils placed symmetrically around the head of the patient. The device delivers 55 Hz magnetic field. Duration of treatment is 30 minutes once a day for 8 weeks.
Study NCT06005103 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive treatment with MoodHeadBand (Placebo)
Description: Patients will use an identical device, which does not deliver T-PEMF treatment. The patients will use the headband as the active group for 30 minutes, once a day, for 8 weeks.
Study NCT05279794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jones Group (Strain Counterstrain)
Description: No pain positioning technique with diaphragmatic breathing
Study NCT05279794 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Induction Group
Description: Myofascial Induction technique on the lumbar fascia
Study NCT05279794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: No pain positioning of participants
Study NCT06111326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BC3402 injection
Description: Intravenous infusion, once every 2 weeks, 4 weeks/cycle.
Study NCT06111326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab injection
Description: Intravenous infusion, once every 4 weeks, 4 weeks/cycle.
Study NCT05496426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL130008/Placebo
Description: Drug: KL130008 Drug: Placebo